FXR agonist 3

• CAT Number: I042384
• Molecular Formula: C28H28BrNO4
• Molecular Weight: 522.43
• Purity: ≥95%
• Synonyms: 2,3,10-trimethoxy-9-[(3-methylphenyl)methoxy]-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium;bromide
• InChI: InChI=1S/C28H28NO4.BrH/c1-18-6-5-7-19(12-18)17-33-28-23-16-29-11-10-21-14-26(31-3)27(32-4)15-22(21)24(29)13-20(23)8-9-25(28)30-2;/h5-9,12-16H,10-11,17H2,1-4H3;1H/q+1;/p-1
• InChIKey: ZJDFWYFAYRTEHX-UHFFFAOYSA-M
• SMILES: CC1=CC(=CC=C1)COC2=C(C=CC3=CC4=[N+](CCC5=CC(=C(C=C54)OC)OC)C=C32)OC.[Br-]

FXR Agonist 3 (Cat No.: I042384) is a synthetic small-molecule activator of the farnesoid X receptor (FXR), a nuclear receptor that regulates bile acid metabolism, lipid homeostasis, and glucose balance. By stimulating FXR, this compound modulates gene expression involved in liver function, inflammation, and metabolic pathways. FXR Agonist 3 is widely used in preclinical studies to investigate therapeutic strategies for conditions such as non-alcoholic steatohepatitis (NASH), cholestatic liver diseases, and metabolic syndrome. It serves as a valuable tool in hepatology and metabolic disease research.

Reference

[1]. Zhang N, et al. Discovery and development of palmatine analogues as anti-NASH agents by activating farnesoid X receptor (FXR). Eur J Med Chem. 2023 Jan 5;245(Pt 1):114886.
[Content Brief]